Stereotaxis swaps out Hogg as CEO

Stereotaxis, a manufacturer of cardiology instrument control systems, has announced that Michael Kaminski, currently president and chief operations officer (COO) and a member of the board, will assume the title and responsibilities of CEO, effective Jan. 1, 2009.

Kaminski will replace Bevil Hogg, who has served as the CEO since 1997 and will remain a member of the company's board of directors.

The St. Louis-based Stereotaxis said that Kaminski came on board in April 2002 as COO. Prior to that, Kaminski spent nearly 20 years with Batesville, Ind.-based Hill-Rom, a provider of hospital and home healthcare equipment.  

"We have reached a point where my own expertise in creating a new technology and the organization to support it should ideally be succeeded by a leader who brings the experience, expertise and focus necessary for operational execution and who can lead Stereotaxis to greater commercial success,” according to Hogg.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.